Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
First patient is dosed in a 370-patient in Phase 3 trial of APP13007 in the US. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline and royalties from the commercialization of certain products should they reach the market.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Ophthalmology Product Name: APP13007
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Sosei Heptares
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2021